CC16 in Childhood and Resilience to Persistent Asthma into Adult Life (Supplement)

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    National Institutes of Health (NIH)
  • Principle Investigator

  • Research Location

    United States of America, Americas
  • Lead Research Institution

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details


  • Broad Policy Alignment


  • Age Group


  • Vulnerable Population


  • Occupations of Interest



PROJECT SUMMARYIn response to NOT-AI-20-031 ["Notice of Special Interest: Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)"] and in line with the scope of the parent grant, thegoal of this supplement is to determine the role of Club cell secretory protein (CC16) in providingresilience to COVID-19. CC16 is a homodimeric pneumoprotein that is encoded by the SCGB1A1 gene,mainly produced by Club cells in the distal airways, and readily measured in circulation.The central hypothesis of our parent grant is that CC16 exerts protective effects in the lungs by modulatingsusceptibility and inflammatory responses to airway infections. In addition, because CC16-secreting Club cellsare among the main airway cell types expressing Angiotensin-Converting Enzyme 2 (ACE2), it is plausible that- by infecting Club cells - SARS-CoV-2 can affect their survival and/or secretory machinery, and in turn impactproduction of CC16. Here, we postulate that CC16 plays a critical role in susceptibility and host inflammatoryresponses to SARS-CoV-2 and propose the following specific aim:Specific Aim - To determine the relation of circulating CC16 to the presence and clinical progression ofCOVID-19.In this pilot study, we will collect clinical data and biospecimens from both inpatients and outpatients withCOVID-19 at Banner University Medical Center - Tucson. Depending on the dynamics of the pandemic, weestimate that we will recruit between 75-125 inpatients and 100-200 outpatients. In addition, we will recruit agroup of controls (with a target case:control ratio of 2:1). Data from these participants will be used to comparecirculating levels of CC16 across the three groups of controls, COVID-19 outpatients, and COVID-19inpatients. In addition, circulating deficits of CC16 will be tested for prediction of subsequent clinicalprogression of disease.